GCG and metabolic dysfunction-associated steatohepatitis: Furthermore, as GLP-1 agonists mainly improve the underlying harmful metabolic dysfunction first, the entire long-term improvement of NASH and fibrosis might require even more prolonged treatment and follow-up period.